Key points

  • Inhibrx Biosciences chief executive Mark Lappe bought $840,401 of company stock dated October 14th, 2026. The purchases covered 9,940 shares.
  • The buying was reported across five Form 4 filings rather than one. Execution prices ran from $84.0707 to $85.76.
  • The stock last printed at $85.26, inside the range the CEO paid. That puts the purchase price and the current quote close together rather than far apart.
  • Inhibrx Biosciences carries a market capitalization of $1,254,827,776. Against that figure, the purchase is a personal commitment rather than a balance sheet event.

Mark Lappe, chief executive officer of Inhibrx Biosciences, Inc. (INBX), bought 9,940 shares of the company on October 14th, 2026. The total came to $840,401.

The transactions were disclosed in five Form 4 filings. Prices on those purchases ranged from $84.0707 to $85.76, and the most recent quote on the stock is $85.26.

What the filing shows

The filings identify the buyer as Lappe Mark, serving as chief executive officer. The transaction date on the purchases is October 14th, 2026. The reported totals are 9,940 shares for $840,401.

Five filings for a single transaction date usually reflects execution split across separate tickets or separate reporting lines rather than five distinct decisions on five days. What matters for a reader is the aggregate, and the aggregate here is $840,401 of stock bought by the person who runs the company.

What the insiders did

This is open market activity by an individual, not an institution. The buyer is the CEO, which is the officer seat that carries the broadest view of a biotechnology company's pipeline timing, cash position and partnering conversations. That is why the market reads chief executive purchases differently from purchases by a director who sits on the board a handful of times a year.

It is also worth being careful about what a Form 4 does and does not say. The form records that shares changed hands, at what price, and on what date. It does not record motive. Nothing in the filing explains the decision, and no explanation should be inferred from the size alone.

The spread between the low and high execution prices, $84.0707 to $85.76, is narrow. Purchases clustered that tightly suggest the buying happened over a short window rather than being worked over weeks at drifting prices.

How the price sits

Inhibrx Biosciences last traded at $85.26. That sits above the low end of the CEO's range and below the high end, meaning the stock has neither run away from the purchase nor fallen beneath the whole of it.

Inhibrx Biosciences operates in biological products, excluding diagnostic substances. Companies in that group tend to trade on clinical readouts, regulatory calendars and financing needs rather than on quarterly revenue lines, which makes insider transaction records one of the few regular disclosures an outside reader can anchor to between data events.

What that leaves

The arithmetic of the position is straightforward. A market capitalization of $1,254,827,776 sits against a single insider purchase of $840,401. The purchase does not change the share count in any meaningful way and does not alter the company's funding picture.

What it does change is the disclosure record. The chief executive now has 9,940 additional shares bought at his own cost, dated October 14th, 2026, in the public file. Readers tracking this name can measure future filings against that line, including any sales, any option exercises and any further purchases.

The things to watch from here are ordinary ones. Whether other officers and directors file purchases near the same price band. Whether Lappe adds again, holds, or begins reporting dispositions. And whether the $84.0707 to $85.76 band ends up looking like a floor the market respected or simply a price that passed through.

Sources: SEC Form 4 filings retrieved via EDGAR and reviewed by InsiderBuying.com, covering transactions dated October 14th, 2026.

Informational only, not investment advice.